Multimodal MRI-guided rTMS to Treat Refractory Hallucinations
- Conditions
- HallucinationsPerceptual DisordersSchizophrenia
- Interventions
- Device: MagPro X100 repetitive Transcranial Magnetic Stimulation
- Registration Number
- NCT01373866
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
* The efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (RCT)
* This study will use a combination of different MRI modalities (fMRI and DTI) to define with precision rTMS brain-targets in the case of multisensory hallucinations
* The investigators anticipate that multimodal MRI-guided rTMS will allow a significant improvement in the efficacy of neuromodulation treatment of refractory hallucinations
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 76
- Right-handed Female/Male, [13-60 y.o.],
- Schizophrenia (DSM-IV-TR diagnosis),
- Drug-resistant hallucinations (Kinon & Kane criteria, 1993),
- Unmodified antipsychotic dosage during the 30 days preceding rMTS,
- No anticonvulsive medication,
- No neurological disorder, no addictive behavior,
- Matched for sex, age and PANSS scores,
- Consent to participate to the study,
- Pregnancy
- Contraindication to MRI scan
- Contraindication to rTMS treatment
- Claustrophobia
- No social insurance
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Conventional T3-P3 rTMS MagPro X100 repetitive Transcranial Magnetic Stimulation - Multimodal MRI-guided rTMS MagPro X100 repetitive Transcranial Magnetic Stimulation -
- Primary Outcome Measures
Name Time Method Severity and Frequency of Hallucinations Assessed at baseline (t0) and longitudinally after the 10 rTMS sessions during the following month (D+15, M+1, M+3, M+6, M+12) Visual Analogue Scale (Severity)/ Visual Analogue Scale (Frequency rate)
- Secondary Outcome Measures
Name Time Method MRI changes Assessed at baseline (t0) and 1 month after the rTMS sessions (M+1) structural MRI/ functional MRI/ Diffusion Tensor Imaging/ MR-spectroscopy
Clinical State Assessed at baseline (t0) and longitudinally after the 10 rTMS sessions during the following month (D+15, M+1, M+3, M+6, M+12) Clinical Global Improvement \[CGI\]/ Positive \& Negative Symptoms Scale \[PANSS\]/ Global Assessment of Functioning \[GAF\].
For the auditory modality: Add the Auditory Hallucinations rating Scale \[AHRS\] frequency scale and total score/ Add the computerized Binary Scale of Auditory Speech Hallucinations \[cbSASH\]
Trial Locations
- Locations (2)
Lille University Hospital Centre
🇫🇷Lille, France
Saint-Anne Psychiatric Hospital
🇫🇷Paris, France